Secondary analysis of the HERO RCT (755 people who inject drugs treated for HCV): alcohol scores did not differ by SVR or care model; within those achieving SVR, AUDIT-C scores fell at all follow-ups vs baseline.
Secondary analysisn = 755
Waters et al. Achieving SVR is associated with long term reduced hazardous alcohol use for people who inject drugs receiving HCV treatment: The HERO study